The bacterium Clostridioides difficile (C. difficile) forms organelles that help them defend against iron in the colon. According to a group of scientists from Vanderbilt University, this pathogen, which causes serious gastrointestinal infections, expresses fez genes to build structures called ferrosomes that store excess iron that is toxic to it. Its ferrosomes are surrounded by membrane and could be a target against this microorganism.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.
Emergex Vaccines Holding Ltd. has signed a contract with the U.K. Department of Health and Social Care (DHSC) for almost £1.8 million (US$2.2 million) to advance a CD8 T cell-based vaccine candidate against Chikungunya virus (CHIKV).
Researchers from Aligos Therapeutics Inc. presented preclinical data for ALG-001075, a novel capsid assembly modulator leading to the formation of empty capsids (CAM-E), being developed for the treatment of hepatitis B.
Researchers from the University of Queensland discovered that senolytic therapies can suppress long-COVID neuropathology and long-term disorders caused by viral infections by reducing senescent cells, thereby reducing inflammation. Published Nov. 13, 2023, in Nature, the study examined the use of human pluripotent stem cells to generate small mini human brain organoids to screen for antiaging interventions called senolytics that selectively eliminate senescent cells that accumulate with age, lead author Julio Aguado told BioWorld.
Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.
Researchers from Aligos Therapeutics Inc. have presented the discovery and preclinical evaluation of a novel next-generation liver targeted PD-L1 small molecule inhibitor, ALG-094103, which is being developed for the treatment of chronic hepatitis B and liver cancer.
It’s known that interferon-alpha (IFNα) activates interferon-stimulated genes (ISGs) and disrupts the hepatitis B virus (HBV) replication cycle. Pegylated (PEG)-IFNα has been widely used for its immunomodulatory and antiviral properties but it is not always well tolerated and thus its use is limited.
The Innovative Medicines Initiative’s COMBINE (COllaboration for prevention and treatment of MDR Bacterial INfEctions) project is developing a standardized in vivo pneumonia model to test small-molecule antibiotics.
RSS
